Close Menu

Cancer Genetics

The decision opens up the largest market in the country to the firm's lymphoma and leukemia testing services.

The firm was not in compliance with minimum bid price and minimum stockholders' equity requirements to remain listed. 

Cancer Genetics CEO Panna Sharma told GenomeWeb this week that the company plans to focus on very targeted panels of actionable mutations.

The company has been told by Nasdaq that it falls short of a listing requirement for at least $2.5 million in stockholders' equity.

The company can now market and report results from its ResponseDX tests to residents of New York.

NEW YORK (GenomeWeb) – Response Genetics today said that its third quarter revenues rose 9 percent year over year on higher testing revenues and volumes.

NEW YORK (GenomeWeb) – Cancer Genetics said today that its third quarter revenues shot up 88 percent year over year on clinical testing volume growth and the close of two acquisitions during the quarter.

NEW YORK (GenomeWeb) – Cancer Genetics today announced a collaboration with Columbia University researchers to identify more accurate diagnostic and prognostic biomarkers for myelodysplastic syndromes.

NEW YORK (GenomeWeb) – Cancer Genetics and Beth Israel Deaconess Medical Center have partnered to study genomic biomarkers in non-Hodgkin lymphoma patients and correlate those markers with clinical outcomes, CGI said today.

NEW YORK (GenomeWeb) – Cancer Genetics has received CE marking for its DNA probe-based in vitro diagnostic cervical cancer screening test, the company said today.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.